Roche Holding Ltd. (OTCMKTS:RHHBY) has been assigned a consensus rating of “Hold” from the fifteen brokerages that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $38.00.
RHHBY has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Roche from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Societe Generale lowered shares of Roche from a “hold” rating to a “sell” rating in a report on Monday, January 15th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Roche in a report on Friday, December 29th. Piper Jaffray Companies restated a “buy” rating on shares of Roche in a report on Thursday, December 7th. Finally, ValuEngine upgraded shares of Roche from a “hold” rating to a “buy” rating in a report on Tuesday, January 16th.
Large investors have recently made changes to their positions in the stock. Lenox Wealth Management Inc. raised its stake in Roche by 49.0% during the 3rd quarter. Lenox Wealth Management Inc. now owns 98,282 shares of the company’s stock worth $3,145,000 after acquiring an additional 32,335 shares in the last quarter. Kidder Stephen W raised its stake in Roche by 1.7% during the 4th quarter. Kidder Stephen W now owns 119,660 shares of the company’s stock worth $3,779,000 after acquiring an additional 1,989 shares in the last quarter. Delaney Dennis R raised its stake in Roche by 160.8% during the 4th quarter. Delaney Dennis R now owns 26,900 shares of the company’s stock worth $850,000 after acquiring an additional 16,585 shares in the last quarter. Tower Bridge Advisors raised its stake in Roche by 2.4% during the 4th quarter. Tower Bridge Advisors now owns 256,039 shares of the company’s stock worth $8,096,000 after acquiring an additional 6,083 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS raised its stake in Roche by 6.3% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 302,864 shares of the company’s stock worth $9,564,000 after acquiring an additional 17,950 shares in the last quarter. Hedge funds and other institutional investors own 0.58% of the company’s stock.
Shares of Roche (OTCMKTS:RHHBY) traded up $0.53 on Wednesday, hitting $29.21. 6,427,128 shares of the stock were exchanged, compared to its average volume of 2,440,000. Roche has a fifty-two week low of $28.48 and a fifty-two week high of $36.82. The firm has a market cap of $204,110.00, a price-to-earnings ratio of 21.96, a price-to-earnings-growth ratio of 1.75 and a beta of 0.59. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.29 and a quick ratio of 0.92.
COPYRIGHT VIOLATION WARNING: This story was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://ledgergazette.com/2018/03/19/brokerages-set-roche-holding-ltd-rhhby-price-target-at-38-00.html.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.